# AbbVie Inc.  Share Price Target ‘$208.32’, now -1.5% Downside Potential

- Link: https://www.directorstalkinterviews.com/abbvie-inc-share-price-target-208-32-now-1-5-downside-potential/4121188104
- Published: 2025-03-05T12:29:30+00:00
- Author: Charlotte Edwards

**AbbVie Inc.** which can be found using ticker (ABBV) now have 26 confirmed analysts
covering the stock with the consensus suggesting a rating of ‘buy’. The target price
High/Low ranges between $250.00 and $165.00 and has a mean share price target at
$208.32. (at the time of writing). Now with the previous closing price of $211.48
this is indicating there is a potential downside of -1.5%. It’s also worth noting
that there is a 50 day moving average of $184.55 and the 200 day moving average 
is $182.32. The total market capitalization for the company now stands at 366.77B.
The price for the stock stands currently at: $207.76 USD

 The potential market cap would be $361,296,745,248 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 86.93, revenue per share of $31.85
and a 8.26% return on assets.

AbbVie Inc. (AbbVie) is a diversified research-based biopharmaceutical company. 
The Company is engaged in the research and development, manufacturing, commercialization
and sale of medicines and therapies. It offers products in various therapeutic categories,
including immunology products, which include Humira, Skyrizi and Rinvoq; oncology
products, which include Imbruvica and Venclexta/Venclyxto; aesthetics products that
include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience
products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye
care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis,
and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella
and Synthroid. Its products are sold to wholesalers, distributors, government agencies,
health care facilities, specialty pharmacies, and independent retailers from the
AbbVie-owned distribution centers and public warehouses.

Share on:
